Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces the efficacy of applying the treatment to the entire population of patients with SCLC. The lack of treatments able to bind to a specific target has always been a substantial difference to the non-small cell lung cancer (NSCLC) counterpart. Delta-like canonical Notch ligand 3 is a protein frequently overexpressed in SCLC and is therefore being explored as a potentially promising therapeutic target in high-grade neuroendocrine lung cancer. In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failures through new compounds and their possible applications in clinical practice, with a focus on new molecular classification of SCLC.

Cortinovis, D., Colonese, F., Abbate, M., Sala, L., Meazza Prina, M., Cordani, N., et al. (2022). Harnessing DLL3 inhibition: From old promises to new therapeutic horizons. FRONTIERS IN MEDICINE, 9 [10.3389/fmed.2022.989405].

Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

Cortinovis D. L.;Abbate M. I.;Cordani N.;
2022

Abstract

Small-cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with a high relapse rate, limited therapeutic options, and poor prognosis. The combination of chemotherapy and immune-checkpoint inhibitors brings a new therapeutic era, although the lack of predictive biomarkers of response reduces the efficacy of applying the treatment to the entire population of patients with SCLC. The lack of treatments able to bind to a specific target has always been a substantial difference to the non-small cell lung cancer (NSCLC) counterpart. Delta-like canonical Notch ligand 3 is a protein frequently overexpressed in SCLC and is therefore being explored as a potentially promising therapeutic target in high-grade neuroendocrine lung cancer. In this article, we critically review the activity and efficacy of old DLL3 inhibitors antibody-drug conjugate (ADC) and their failures through new compounds and their possible applications in clinical practice, with a focus on new molecular classification of SCLC.
Articolo in rivista - Articolo scientifico
DLL3; molecular classification; rovalpituzumab tesirine; small-cell lung cancer; tarlatamab;
English
2022
9
989405
none
Cortinovis, D., Colonese, F., Abbate, M., Sala, L., Meazza Prina, M., Cordani, N., et al. (2022). Harnessing DLL3 inhibition: From old promises to new therapeutic horizons. FRONTIERS IN MEDICINE, 9 [10.3389/fmed.2022.989405].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/406056
Citazioni
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
Social impact